VIR

VIR BIOTECHNOLOG
NASDAQ

Real-time Quotes | Nasdaq Last Sale

28.97
-0.80
-2.69%
Opening 12:25 04/02 EDT
OPEN
29.96
PREV CLOSE
29.77
HIGH
30.39
LOW
28.32
VOLUME
224.13K
TURNOVER
--
52 WEEK HIGH
75.00
52 WEEK LOW
11.65
MARKET CAP
3.18B
P/E (TTM)
-5.0295
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 5 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average VIR stock price target is 33.33 with a high estimate of 41.00 and a low estimate of 20.00.

EPS

VIR News

More
  • The Daily Biotech Pulse: Novartis Scraps Deal To Sell Sandoz Assets, Nevro Pre-Announces Q1 Shortfall, Affimed Granted Orphan Drug Designation
  • Benzinga · 4h ago
  • COVID-19 actions - healthcare
  • Seeking Alpha - Article · 4h ago
  • Vir Biotech, Alnylam Pharma To Expand Multi-Target Existing Collaboration For Development, Commercialization Of RNAi Therapeutics, Including Coronavirus Infection
  • Benzinga · 5h ago
  • Covid-19 activity roundup - healthcare
  • seekingalpha · 2d ago

Industry

Biotechnology & Medical Research
+2.27%
Pharmaceuticals & Medical Research
+1.66%

Hot Stocks

Symbol
Price
%Change

About VIR

Vir Biotechnology, Inc. is a clinical-stage immunology company. The Company is focused on developing treatments to treat and prevent serious infectious diseases. Its technology platforms are focused on antibodies, T cells, innate immunity and small interfering ribonucleic acid (siRNA). Its pipeline consists of product candidates targeting hepatitis B virus (HBV), influenza A, human immunodeficiency virus (HIV) and tuberculosis (TB). Its product candidates include VIR-2218, VIR-3434, VIR-2482, VIR-1111 and VIR-2020. The Company is developing VIR-2218 and VIR-3434 for the functional cure of HBV. VIR-2218 is a subcutaneously administered HBV-targeting siRNA. VIR-3434 is a subcutaneously administered HBV-neutralizing monoclonal antibody (mAb). VIR-2482 is an intramuscularly administered influenza A-neutralizing mAb. VIR-1111 is a subcutaneously administered HIV T cell vaccine. VIR-2020 is a subcutaneously administered TB T cell vaccine.
More

Webull offers kinds of Vir Biotechnology Inc stock information, including NASDAQ:VIR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VIR stock news, and many more online research tools to help you make informed decisions.